CYTK Q3 2020 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+588.5% YoY

Gross Profit

$17M41.9% margin

Operating Income

$5M12.4% margin

Net Income

-$3M-7.6% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+1060.3%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$12M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$474M

Total Liabilities

$325M

Stockholders' Equity

$150M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$6M	+588.5%
Gross Profit	$17M	-$14M	+223.4%
Operating Income	$5M	-$24M	+121.7%
Net Income	-$3M	-$30M	+89.3%

Revenue Segments

Research And Development

$5M58%

Research And Development Milestone Grant And Other Revenues Net

$4M42%